Journal ArticleDOI
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Meletios A. Dimopoulos,Hang Quach,Maria-Victoria Mateos,Ola Landgren,Xavier Leleu,David S. Siegel,Katja Weisel,Hui Yang,Zandra Klippel,Anita Zahlten-Kumeli,Saad Z. Usmani +10 more
TLDR
KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile.About:
This article is published in The Lancet.The article was published on 2020-07-18. It has received 257 citations till now. The article focuses on the topics: Carfilzomib & Daratumumab.read more
Citations
More filters
Journal ArticleDOI
Inflammation and tumor progression: signaling pathways and targeted intervention.
TL;DR: In this article, the authors discuss the initiation and resolution of inflammation, the crosstalk between tumor development and inflammatory processes, and highlight potential targets for harnessing inflammation in the treatment of cancer.
Book ChapterDOI
Institute for Clinical and Economic Review
TL;DR: Changes include separation of budget impact analysis from value determinations, introduction of other value measures beyond the QALY, increasing consideration of contextual elements, and adoption of a “societal perspective” where data support it.
Journal ArticleDOI
Diagnosis and Management of Multiple Myeloma: A Review.
Andrew J. Cowan,Damian J. Green,Mary Kwok,Sarah S. Lee,David C. Coffey,Leona Holmberg,Sherilyn A. Tuazon,Ajay K. Gopal,Edward N. Libby +8 more
TL;DR: The Revised International Staging System combines data from the serum biomarkers β2 microglobulin, albumin, and lactate dehydrogenase in conjunction with malignant plasma cell genomic features found on fluorescence in situ hybridization to assess estimated progression-free survival and overall survival.
Journal ArticleDOI
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Philippe Moreau,Meletios-Athanasios Dimopoulos,Joseph Mikhael,Kwee Yong,Marcelo Capra,Thierry Facon,Roman Hájek,Ivan Spicka,Ross I. Baker,Kihyun Kim,Gracia Martinez,Chang-Ki Min,Ludek Pour,Xavier Leleu,Albert Oriol,Youngil Koh,Kenshi Suzuki,Marie-Laure Risse,Gaëlle Asset,Sandrine Macé,Thomas Martin +20 more
TL;DR: In this article, the authors compared the efficacy of isatuximab plus carfilzomib-dexamethasone versus CARF-DEXAMETHASONE in patients with relapsed or refractory multiple myeloma.
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Meletios A. Dimopoulos,Philippe Moreau,Evangelos Terpos,Maria-Victoria Mateos,Sonja Zweegman,Gordon Cook,Michel Delforge,Roman Hájek,Fredrik Schjesvold,Michele Cavo,Hartmut Goldschmidt,Thierry Facon,Hermann Einsele,Mario Boccadoro,Jesús F. San-Miguel,Pieter Sonneveld,Ulrich Mey +16 more
References
More filters
Journal ArticleDOI
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar,S. Vincent Rajkumar,Angela Dispenzieri,Martha Q. Lacy,Suzanne R. Hayman,Francis K. Buadi,Steven R. Zeldenrust,David Dingli,Stephen J. Russell,John A. Lust,Philip R. Greipp,Robert A. Kyle,Morie A. Gertz +12 more
TL;DR: Improved outcome of patients with myeloma in recent years is demonstrated, both in the relapsed setting as well as at diagnosis, both from time of diagnosis and the time of relapse.
Journal ArticleDOI
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar,Bruno Paiva,Kenneth C. Anderson,Brian G.M. Durie,Ola Landgren,Philippe Moreau,Nikhil C. Munshi,Sagar Lonial,Joan Bladé,Maria-Victoria Mateos,Meletios A. Dimopoulos,Efstathios Kastritis,Mario Boccadoro,Mario Boccadoro,Robert Z. Orlowski,Hartmut Goldschmidt,Andrew Spencer,Jian Hou,Wee Joo Chng,Saad Z. Usmani,Elena Zamagni,Kazuyuki Shimizu,Sundar Jagannath,Hans Erik Johnsen,Evangelos Terpos,Anthony Reiman,Robert A. Kyle,Pieter Sonneveld,Paul G. Richardson,Philip L. McCarthy,Heinz Ludwig,Wenming Chen,Michele Cavo,Jean Luc Harousseau,Suzanne Lentzsch,Jens Hillengass,Antonio Palumbo,Alberto Orfao,S. Vincent Rajkumar,Jesús F. San Miguel,Hervé Avet-Loiseau +40 more
TL;DR: Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials.
Journal ArticleDOI
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo,Asher Chanan-Khan,Katja Weisel,Ajay K. Nooka,Tamás Masszi,Meral Beksac,Ivan Spicka,Vania Hungria,Markus Munder,Maria-Victoria Mateos,Tomer M Mark,Ming Qi,Jordan M. Schecter,Himal Amin,Xiang Qin,William Deraedt,Tahamtan Ahmadi,Andrew Spencer,Pieter Sonneveld +18 more
TL;DR: Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Journal ArticleDOI
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
TL;DR: The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Journal ArticleDOI
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
TL;DR: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk–benefit profile.
Related Papers (5)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos,Albert Oriol,Hareth Nahi,Jesús F. San-Miguel,Nizar J. Bahlis,Saad Z. Usmani,Neil Rabin,Robert Z. Orlowski,Mieczysław Komarnicki,Kenshi Suzuki,Torben Plesner,Sung-Soo Yoon,Dina Ben Yehuda,Paul G. Richardson,Hartmut Goldschmidt,Hartmut Goldschmidt,Donna E. Reece,Steen Lisby,Nushmia Z. Khokhar,Lisa O'Rourke,Christopher Chiu,Xiang Qin,Mary E. Guckert,Tahamtan Ahmadi,Philippe Moreau +24 more
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Thierry Facon,Shaji Kumar,Torben Plesner,Robert Z. Orlowski,Philippe Moreau,Nizar J. Bahlis,Supratik Basu,Hareth Nahi,Cyrille Hulin,Hang Quach,Hartmut Goldschmidt,Michael O'Dwyer,Aurore Perrot,Christopher P. Venner,Katja Weisel,Joseph R. Mace,Noopur Raje,Michel Attal,Mourad Tiab,Margaret Macro,Laurent Frenzel,Xavier Leleu,Tahamtan Ahmadi,Christopher Chiu,Jianping Wang,Rian Van Rampelbergh,Clarissa M. Uhlar,Rachel Kobos,Ming Qi,Saad Z. Usmani,Maia Trial Investigators +30 more
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau,Michel Attal,Cyrille Hulin,Bertrand Arnulf,Karim Belhadj,Lotfi Benboubker,Marie C. Béné,Annemiek Broijl,Hélène Caillon,Denis Caillot,Jill Corre,Michel Delforge,Thomas Dejoie,Chantal Doyen,Thierry Facon,Cécile Sonntag,Jean Fontan,Laurent Garderet,Kon-Siong Jie,Lionel Karlin,Frédérique Kuhnowski,Jérôme J. Lambert,Xavier Leleu,Pascal Lenain,Margaret Macro,Claire Mathiot,Frédérique Orsini-Piocelle,Aurore Perrot,Anne-Marie Stoppa,Niels W.C.J. van de Donk,Soraya Wuilleme,Sonja Zweegman,Brigitte Kolb,Cyrille Touzeau,Murielle Roussel,Mourad Tiab,Jean-Pierre Marolleau,Nathalie Meuleman,Marie-Christiane Vekemans,Matthijs Westerman,Saskia K. Klein,Mark-David Levin,Jean Paul Fermand,Martine Escoffre-Barbe,Jean-Richard Eveillard,Reda Garidi,Tahamtan Ahmadi,Sen Zhuang,Christopher Chiu,Lixia Pei,Carla de Boer,Elena Smith,William Deraedt,Tobias Kampfenkel,Jordan M. Schecter,Jessica Vermeulen,Hervé Avet-Loiseau,Pieter Sonneveld +57 more